Medical/Pharmaceuticals
First Patient Dosed in Phase Ⅲ Study of JSKN003 for the Treatment of Advanced HER2-Low Breast Cancer
SUZHOU, China, Dec. 4, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the first patient has been dosed in the phase III clinical study (JSKN003-302) of anti-HER2 bispecific antibody-drug conjugate JSKN003 for treatment of advanced HER2-low breast cancer. Breast cancer is ...
Nona Biosciences Announces Collaboration Agreement with Lycia Therapeutics
CAMBRIDGE, Mass., Dec. 3, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, announced today it has entered into a collaboration agreement with Lycia Therapeutics, a leader in extracellular protein degradation. Lycia...
First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent
MELBOURNE, Australia and LIÉGE, Belgium, Dec. 4, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a named patient (early access) program inthe Netherlands for its investigational positron emission tomography...
VISTA Eye Specialist introduces CLEAR - a new generation eye surgery to help patients be glasses free again.
PETALING JAYA, Malaysia, Dec. 4, 2023 /PRNewswire/ -- VISTA Eye Specialist (VISTA) proudly announces the successful introduction of CLEAR (Corneal Lenticule Extraction for Advanced Refractive Correction), an advanced version of the Lenticule Extraction treatment used to correct Short-sightedness ...
The 3rd International Medical Innovation and Cooperation Forum convenes in Fangchenggang
Enhancing Global Medical Collaboration and Advancing Shared Development through Inclusive Exchange BEIJING, Dec. 4, 2023 /PRNewswire/ -- On 26 November, the 3rd International Medical Innovation and Cooperation Forum was held in Fangchenggang, Guangxi Zhuang Autonomous Region,China. The forum, ...
Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China
-- Everest plans to contribute to the ongoing global Phase 2b PALIZADE trial of zetomipzomib in active lupus nephritis – -- Zetomipzomib demonstrated clinically meaningful renal responses with a favorable tolerability profile in an earlier Phase 2 trial -- -- Renal and autoimmune diseases are k...
Media Tour Witnesses Chinese Modernization in Hainan FTP
HAIKOU, China, Dec. 3, 2023 /PRNewswire/ -- From November 27 to December 1, a group made up of more than 60 reporters, overseas communication officers, and social media personalities got their chance to witness the development of the Hainan Free Trade Port (FTP) up close, as they visited key indu...
The highest incidence of OHCA is at home, with 3 cases of young OHCA occurring at home every week.
Be a brave first responder and save your loved ones' lives. HONG KONG, Dec. 1, 2023 /PRNewswire/ -- SADS HK Foundation (SADS HK) has commissioned the Department of Rehabilitation Sciences of The Hong Kong Polytechnic University (PolyU) to conduct research on the "Out-of-Hospital Cardiac Arrest (...
280Bio doses first patient in Phase I clinical trial of TEB-17231, an oral pan-RAS inhibitor in patients with advanced cancers harboring mutations in KRAS, HRAS, or NRAS
SOUTH SAN FRANCISCO, Calif., Dec. 1, 2023 /PRNewswire/ -- 280Bio, Inc., a clinical stage biotechnology company focused on the development of precision oncology medicines, today announced that the first patient was treated with TEB-17231 (YL-17231), a small molecule inhibitor of RAS signaling. 280...
The Shanghai Cooperation Organization Traditional Medicine Forum opened
NANCHANG, China, Dec. 1, 2023 /PRNewswire/ -- The Shanghai Cooperation Organization Traditional Medicine Forum opened in Ganjiang New District,Jiangxi Province on November 30, 2023, with the theme of "Inheritance and innovation, unity and cooperation, promoting high-quality development of traditi...
GC Biopharma establishes mRNA production facility in Hwasun, Korea
* Completed the construction of a GMP pilot plant in its Hwasun production plant in Jeollanam-do, Korea * Plans to expand its domain from vaccine development to the field of rare disease treatments by proactively securing mRNA platforms YONGIN, South Korea, Dec. 1, 2023 /PRNewswire/ -- GC Bio...
Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer
HONG KONG, Germantown, Md. and Suzhou, China, Dec. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today...
Innovent Presents Clinical Data Update of IBI351 (KRAS G12C Inhibitor) Monotherapy in Lung Cancer and Colorectal Cancer at ESMO Asia Congress 2023
ROCKVILLE, Md. and SUZHOU, China, Dec. 1, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...
CNN's 'Vital Signs' explores the prospects of phage therapy to treat drug-resistant superbugs
HONG KONG, Dec. 1, 2023 /PRNewswire/ -- Antibiotics have been hailed as a "miracle drug" since the discovery of penicillin in 1928, but now, more bacteria are developing resistance to antibiotics. In 2019, the United Nations estimated nearly 5 million deaths were associated with antimicrobial re...
Cerecin forges strategic partnership with A*STAR's Institute of Molecular and Cell Biology (IMCB) in Singapore to advance R&D in neurological disorders.
Cerecin and IMCB signed a Memorandum of Understanding to collaborate in the areas of neurometabolism, neurodegeneration, metabolic regulators, and brain health and function. SINGAPORE and DENVER, Dec. 1, 2023 /PRNewswire/ -- Cerecin Inc., a clinical-stage biotechnology company at the forefront o...
Everest Medicines Announces Positive Topline Results from Induction Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderate-to-Severe Active Ulcerative Colitis
--Clinically meaningful and statistically significant results demonstrated for primary endpoint and key secondary endpoints for the 12-week induction period-- --Etrasimod was well-tolerated and its safety profile was consistent with prior studies-- --Everest will advance the late-stage study as...
Biocon Biologics Successfully Completes Integration of Viatris' Biosimilar Business in 31 Countries in Europe
BENGALURU, India, Dec. 1, 2023 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the integration of the Viatris' biosimilars business in 31 European countries has been successfully completed. Following the acquisition of ...
Allotex Announces New Investor and Expansion of Production Facilities
BOSTON and MILAN, Dec. 1, 2023 /PRNewswire/ -- Allotex Inc. and SpA, a leading biologics and device company specializing in vision correction therapies, is pleased to announce that Junson Capital has joined its investor syndicate. This additional capital will help support the expansion of the Com...
Bushu Pharma Recognized with Frost & Sullivan's 2023 Japan Customer Value Leadership Award for Offering Advanced Pharmaceutical Manufacturing and Robust Supply Chain Solutions
Bushu Pharma produces high-quality pharmaceutical and medical devices with sophisticated quality control and supply chain management support that prioritizes customer value. SAN ANTONIO, Nov. 30, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the contract development and manufacturing...
Argon Medical Launches Kodiak™ Dual Port Coaxial Introducer Kit for Complex Vascular Procedures
PLANO, Texas, Nov. 30, 2023 /PRNewswire/ -- Argon Medical Devices, a leading provider of device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology, announced the launch of the Kodiak™ Dual Port Coaxial Introducer Kit for precise and streamlined intro...
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 324 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 309 media titles]
2024-04-15 17:33AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
[Picked up by 295 media titles]
2024-04-12 15:14LEGOLAND® School Challenge 2024 Expands Across Asia and Opens for Registration on April 15th
[Picked up by 276 media titles]
2024-04-11 11:00Allianz Partners Introduces Instant Online Chat for HCF Travel Insurance Customers
[Picked up by 275 media titles]
2024-04-15 08:00